Briefs: Medicamen Biotech and Gland Pharma
Drug Approval

Briefs: Medicamen Biotech and Gland Pharma

Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

  • By IPP Bureau | January 08, 2026

Medicamen Biotech gets EU approval for Paracetamol from Danish Medicine Authority

Medicamen Biotech Limited is pleased to announce for getting EU approval for product registration of "Paracetamol" from Danish Medicine Authority with XGX Pharma, Denmark.

Gland Pharma receives approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)

Gland Pharma Limited (Gland or Company), a generic injectable & ophthalmic focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The Product is therapeutically equivalent to the reference listed drug (RLD), Pataday Once Daily Relief, 0.7%, of Alcon Laboratories Inc (Alcon).

Upcoming E-conference

Other Related stories

Startup

Digitization